IP Library › Granted Patent US 12,453,771
Granted Patent B2
US 12,453,771 · App. 18/051,761 · Granted Oct 28, 2025

Methods of treating cancer using anti-CD137 antibodies

Inventors: Christopher Carl Frye (Bargersville, IN); Michael Dewain Kalos (Brooklyn, NY); Helen Kotanides (Norwalk, CT); Stephanie Lynn Sandefur (Indianapolis, IN)
Assignee: ELI LILLY AND COMPANY
A61K39/3955C07K16/2878C07K2317/21C07K2317/565C07K2317/75
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,453,771
App. No.
18/051,761
Granted
Oct 28, 2025
Kind
B2
Abstract

The present invention relates to antibodies that bind to human CD137 and display agonist activity, and are useful for treating solid and hematological tumors alone and in combination with chemotherapy and ionizing radiation.

Claims (15)

1. A method of treating cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of an anti-human CD137 antibody comprising a heavy chain variable region and a light chain variable region; wherein the heavy chain variable region comprises a HCDR1 having the amino acid sequence of SEQ ID NO: 2, a HCDR2 having the amino acid sequence of SEQ ID NO: 3, and a HCDR3 having the amino acid sequence of SEQ ID NO: 4; wherein the light chain variable region comprises a LCDR1 having the amino acid sequence of SEQ ID NO: 5, a LCDR2 having the amino acid sequence of SEQ ID NO: 6, and a LCDR3 having the amino acid sequence of SEQ ID NO: 7.

2. The method of claim 1 , wherein the antibody contacts amino acid residues 55, 59, 63, 66, 72, 93-103, and 112-116 of human CD137 as set forth in SEQ ID NO: 1, and wherein the amino acid residues in contact are within six (6) angstroms or less of the antibody.

3. The method of claim 1 , wherein the antibody comprises a heavy chain having the amino acid sequence of SEQ ID NO: 10 and a light chain having the amino acid sequence of SEQ ID NO: 11.

4. The method of claim 1 , wherein the antibody comprises a heavy chain having the amino acid sequence of SEQ ID NO: 10 and a light chain having the amino acid sequence of SEQ ID NO: 13.

5. The method of claim 1 , wherein the cancer is adenocarcinoma or squamous cell carcinoma.

6. The method of claim 1 , wherein the cancer is bladder cancer, breast cancer, biliary tract cancer, colon cancer, endometrial cancer, esophageal cancer, gastric cancer, head and neck cancer, non-small cell lung cancer, prostate cancer, rectal cancer, or thyroid cancer.

7. The method of claim 1 , wherein the cancer is at least one of:

adenocarcinoma or squamous cell carcinoma;

and at least one of: bladder cancer, breast cancer, biliary tract cancer, colon cancer, endometrial cancer, esophageal cancer, gastric cancer, head and neck cancer, non-small cell lung cancer, prostate cancer, rectal cancer, or thyroid cancer.

8. The method of claim 1 , wherein the cancer is cholangiocarcinoma, head and neck squamous cell carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, or clear cell renal carcinoma.

9. The method of claim 1 , wherein the cancer is bladder cancer, head and neck squamous cell carcinoma, or renal cell carcinoma.

10. The method of claim 1 , wherein the cancer is a solid tumor, and the tumor is infiltrated with CD137 + lymphocytes.

11. The method of claim 1 , wherein the antibody is administered in combination with ionizing radiation.

12. The method of claim 1 , wherein the antibody is administered in combination with one or more chemotherapeutic agents.

13. The method of claim 12 , wherein the antibody is administered simultaneously, separately, or sequentially with the one or more chemotherapeutic agents.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 1, 2025
From: FRYE, CHRISTOPHER CARL; KALOS, MICHAEL DEWAIN; KOTANIDES, HELEN; SANDEFUR, STEPHANIE LYNN
To: ELI LILLY AND COMPANY
Reel/Frame 071580/0579 →
Continuity (4)
Division 16750842 · Jan 23, 2020
Continuation 16497493
Provisional Application 62539687 · Aug 1, 2017
Related Publication 20230279134A1 · Sep 7, 2023
References Cited (47)
US 6210669B1 · Aruffo et al. · 2001 [cited by applicant]
US 6303121B1 · Kwon · 2001 [cited by applicant]
US 6355779B1 · Goodwin et al. · 2002 [cited by applicant]
US 6569997B1 · Kwon · 2003 [cited by applicant]
US 6974863B2 · Kwon · 2005 [cited by applicant]
US 7288638B2 · Jure-Kunkel et al. · 2007 [cited by applicant]
US 7651686B2 · Chen et al. · 2010 [cited by applicant]
US 8163550B2 · Chen et al. · 2012 [cited by applicant]
US 8337850B2 · Ahrens et al. · 2012 [cited by applicant]
US 8475790B2 · Jure-Kunkel · 2013 [cited by applicant]
US 8772026B2 · Chen et al. · 2014 [cited by applicant]
US 10689454B2 · Ellmark et al. · 2020 [cited by applicant]
US 10906983B2 · Frye et al. · 2021 [cited by applicant]
US 20150210769A1 · Freeman et al. · 2015 [cited by applicant]
US 20160244528A1 · Gray et al. · 2016 [cited by applicant]
WO 2003049755A1 · 2003 [cited by applicant]
WO 2015119923A1 · 2015 [cited by applicant]
WO 2016029073A2 · 2016 [cited by applicant]
WO 2017025016A1 · 2017 [cited by applicant]
WO 2017034916A1 · 2017 [cited by applicant]
Hubbi et al., Regulation of cell proliferation by hypoxia-inducible factors, Am. J. Physiol. Cell Physiol. 309: C775-C782, 2015. [cited by examiner]
Bio X Cell, Catalog #BE0169, “Anti-mouse 4-1bb antibody BE0169,” 2022. Retrieved online: <URL: https://bxcell.com/product/tm-cd 137/>, retrieved on Mar. 2, 2022. [cited by applicant]
Deutscher, M.P. “[8] Maintaining protein stability,” Methods in Enzymology, vol. 182, Academic Press, 1990, pp. 83-89. [cited by applicant]
Emsley, P. et al., “Features and development of Coot,” Acta Crystallographica Section D: Biological Crystallography, 66.4, 2010, pp. 486-501. [cited by applicant]
Fisher, T.S. et al., “Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity,” Cancer Immunology Immunotherapy 2012, 61(10): 1721-1733. [cited by applicant]
Guo, Z. et al., “Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer.” Journal of Translational Medicine 2013, 11(1): 215, 11 pages. [cited by applicant]
Hurtado et al., “Signals through 4-1BB are costimulatory to previously activated splenic T cells and inhibit activation-induced cell death,” J Immunol 1997, 158 (6), pp. 2600-2609. [cited by applicant]
International Search Report of PCT/US2018/043632 (filed Jul. 25, 2018 by Eli Lilly and Company), Mailed by the European Patent Office on Oct. 25, 2018; search completed Oct. 5, 2018, 6 pages. [cited by applicant]
Written Opinion of the International Search Authority of PCT/US2018/043632 (filed Jul. 25, 2018 by Eli Lilly and Company), Mailed by the European Patent Office on Oct. 25, 2018; search completed Oct. 5, 2018, 6 pages. [cited by applicant]
Kotanides et al., “Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity.” Mol Cancer Ther. 2020, 19(4), pp. 988-998. [cited by applicant]
Kunik et al., “Structural consensus among antibodies defines the antigen binding site,” PLoS Comput. Biol. 2012, 8(2):e 1002388, doi: 10.1371/journal.pcbi.1002388. [cited by applicant]
Kwon et al., “4-1BB: Still in the midst of darkness,” Molecules and Cells; Seoul, 2000, vol. 10, Iss. 2, pp. 119-126. [cited by applicant]
Kwon et al., “cDNA sequences of two inducible T-cell genes,” Proc Natl Acad Sci U S A. 1989, 86(6): pp. 1963-1967. [cited by applicant]
Li et al., “Limited cross-linking of 4-1BB by 4-1BB ligand and the agonist monoclonal antibody utomilumab,” Cell Reports, 2018, 25, pp. 909-920. [cited by applicant]
MacCallum et al., “Antibody-antigen interactions: contact analysis and binding site topography,” J. Mol. Biol. 1996, 262:732-745. [cited by applicant]
McCoy, A.J. et al., “Phaser crystallographic software,” Journal of Applied Crystallography, 40.4, 2007, pp. 658-674. [cited by applicant]
McGray et al., “Combined vaccination and immunostimulatory antibodies provides durable cure of murine melanoma and induces transcriptional changes associated with positive outcome in human melanoma patients,” Oncoimmuno… [cited by applicant]
Melero, I. et al., “Monoclonal antibodies aganist the 4-1BB T-cell activation molecule eradicate established tumors,” Nature Medicine, 1997, 3.6, pp. 682. [cited by applicant]
Murshudov, G.N. et al., “REFMAC5 for the refinement of macromolecular crystal structures,” Acta Crystallographica Section D: Biological Crystallography, 2011, 67.4, pp. 355-367. [cited by applicant]
North, B. et al., “A New Clustering of Antibody CDR Loop Conformations,” Journal of Molecular Biology, 2011, 406, pp. 228-256. [cited by applicant]
Perez-Ruiz et al., Anti-CD137 and PD-1/PD-L1 Antibodies En Route toward Clinical Synergy. Clin Cancer Res, 2017, vol. 23, Issue 18, pp. 5326-5328. [cited by applicant]
Robinson et al., “Abstract 3973: Effects of anti-PD-1 and anti-4-1BB antibody treatment on melanoma-specific T cells in a murine model of melanoma,” Cancer Res, 2013, vol. 73. [cited by applicant]
Segal, N.H. et al., “Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody,” Clinical Cancer Research, 2017, 23.8, pp. 1929-1936. [cited by applicant]
Shuford et al. , “4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses,” J Exp Med. 1997; 186(1):47-55. [cited by applicant]
Tolcher et al., “Phase lb Study of Utomilumab (PF-05082566, a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors”, Clin. Cancer Res., 2017 DOI: 10.1158/1078-0432. CCR… [cited by applicant]
Verbrugge et al., “Radiotherapy increases the permissiveness of established mammory tumors to rejection by immunomodulatory antibodies,” Cancer Res., 2012, 72(13), pp. 3163-3174. [cited by applicant]
Winn, M.D. et al., “Overview of the CCP4 suite and current developments,” Acta Crystallographica Section D: Biological Crystallography, 2011, 67.4, pp. 235-242. [cited by applicant]